Top Markets
#1 Seeker Seeker +17.63%
#2 EXOD EXOD +9.04%
#3 Wrapped Aave Ethereum WETH Wrapped Aave Ethereum WETH +7.48%
#4 aelf aelf +6.19%
#5 Solstice Solstice +5.55%
#6 Official Trump Official Trump +4.71%
#7 Derive Derive +4.46%
#8 Wrapped STX (Velar) Wrapped STX (Velar) +4.18%
#9 Arowana Arowana +3.74%
#10 DexNet DexNet +3.67%
Coin of the day
Seeker Seeker
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
Rangering i aksjer #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
Aksjekurs
$64.97
Sist synkronisert: 2024-05-20
Markedsverdi
$1.97B
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Alpine Immune Sciences, Inc. (ALPN)

Kategori

Healthcare
P/E-forhold for Alpine Immune Sciences, Inc. (ALPN)
P/E-forhold per August 2026 TTM: -101.52
Ifølge Alpine Immune Sciences, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) -101.52. Ved slutten av 2022 hadde selskapet en P/E på -4.25.
P/E-forholdshistorikk for Alpine Immune Sciences, Inc. fra 2012 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
2026 (TTM) -101.52 242.84%
2023 -29.61 596.00%
2022 -4.25 -39.31%
2021 -7.01 -25.36%
2020 -9.39 466.64%
2019 -1.66 18.66%
2018 -1.40 -85.02%
2017 -9.33 745.71%
2016 -1.10 -65.30%
2015 -3.18 -64.89%
2014 -9.05 7.73%
2013 -8.40 -40.90%
2012 -14.22 0.00%
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -128.76%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -130.16%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -131.98%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -92.18%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.